Market
Highlights
The
market in Asia Pacific is expected to grow rapidly in the coming years. By
studying and analyzing the market, it shows that this region has a good growth
potential due to increasing unhealthy eating habits and unhygienic conditions.
The other major chronic disease found in this region is the gastric cancer.
Segmentation
The
global chronic idiopathic constipation market is segmented on the basis of
diagnosis, treatment, and end-user. On the basis of diagnosis, the market is
segmented into blood tests, sigmoidoscopy, colonoscopy, balloon expulsion
tests, anorectal manometry, colonic transit study, defecography, and others. On
the basis of treatment, the market is segmented into drug and surgery. Drugs
are further segmented into acid neutralizers, laxatives and antidiarrheal,
antiemetics, antiulcer, lubiprostone (amitiza) and linaclotide (linzess),
misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) and
Onabotulinumtoxin A (also called botulinum toxin type A or Botox), and others.
On the basis of end-user, the market is segmented into hospitals,
gastroenterology clinics, diagnostic centers, and others.
Regional
Analysis
The
Americas dominates the global chronic idiopathic constipation market owing to
the increasing prevalence of chronic constipation and the presence of a
well-developed healthcare sector within the region. Moreover, the increasing
healthcare expenditure and the presence of key players within regional
boundaries provide a favorable background for the market growth.
Europe
is the second largest in the global chronic idiopathic constipation market.
Factors such as the increasing availability of funds for research and a huge
patient population followed by a well-developed healthcare sector drive the
market within the region.
Asia
Pacific is estimated to be the fastest growing market for chronic idiopathic
constipation. This can be attributed to the presence of developing economies
such as India and China and a huge patient population. Moreover, the increasing
healthcare expenditure and a rapidly developing healthcare sector boost the
market growth within the region.
On
the other hand, the Middle East and Africa has the least share in the global
chronic idiopathic constipation market due to the low per capita healthcare
expenditure and stringent government policies, especially within the African
region. It is estimated that the Middle East holds a majority of the market
within the Middle Eastern and African region.
Access
Report Details @ https://www.marketresearchfuture.com/reports/chronic-idiopathic-constipation-market-5931
Key
Players
Some
of the key players in this market are Actavis (U.S.), Chugai
Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy
Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi
(France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo
Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics
Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer
Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals,
Inc. (U.S.), and others.
No comments:
Post a Comment